Proteinases, their inhibitors, and cytokine profiles in acute wound fluid.
Wound healing is a complex process involving the interactions of many different cell types, matrix components and biological factors, including proteinases and cytokines. This study compared the levels of proteinases (matrix metalloproteinases and plasminogen activators), proteinase inhibitors (tissue inhibitors of metalloproteinases and plasminogen activator inhibitors), inflammatory cytokines and growth factors in acute wound fluid samples collected from the surgical drains of elective breast (n = 24) and colorectal (n = 26) patients on the first postoperative day. Gelatin zymography was used to determine matrix metalloproteinase-2 and -9 levels, quenched fluorescence substrate hydrolysis was applied for total MMP activity and enzyme-linked immunoassays were used to quantitate other factors. Colorectal wound fluid samples showed significantly (p < 0.05) greater levels of the matrix metalloproteinases (MMP-1, 2, 3, and 9), tissue inhibitor of metalloproteinases-1, urokinase plasminogen activator receptor and the inflammatory cytokines (interleukin-1beta, -6, and tumor necrosis factor-alpha); e.g., matrix metalloproteinase-3 colon; median 275 (range 11-2.530) ng/ml; breast; 530-400. However, tissue plasminogen activator and growth factor levels (epidermal growth factor, platelet-derived growth factor, basic fibroblast growth factor, transforming growth factor-beta1) were significantly greater in breast samples; e.g., epidermal growth factor breast 468 (103-1, 444) pg/ml; colon 57(1-573). There was no difference in the levels of urokinase type plasminogen activator, plasminogen activator inhibitor-1 and -2, tissue inhibitor of metalloproteinases -2 or vascular endothelial growth factor. Acute wound fluid from different surgical wounds showed different profiles of proteinases, proteinase inhibitors, and cytokines. This may lead to differences in the rate of tissue remodeling and therefore healing in these two wounds in vivo.
Baker
E A
EA
Professorial Unit of Surgery, North Tees General Hospital, Stockton on Tees, United Kingdom. drlizbaker@yahoo.co.uk
Leaper
D J
DJ
D000208:Acute Disease; D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery; D015179:Colorectal Neoplasms / Q000473:pathology / Q000601:surgery; D016207:Cytokines / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005122:Exudates and Transudates / Q000737:chemistry* / Q000201:enzymology / Q000276:immunology; D006133:Growth Substances / Q000032:analysis*; D006801:Humans; D007249:Inflammation; D007375:Interleukin-1 / Q000032:analysis*; D015850:Interleukin-6 / Q000032:analysis*; D020781:Matrix Metalloproteinase 1 / Q000032:analysis*; D020778:Matrix Metalloproteinase 2 / Q000032:analysis*; D019278:Matrix Metalloproteinase 3 / Q000032:analysis*; D020780:Matrix Metalloproteinase 9 / Q000032:analysis*; D061965:Matrix Metalloproteinase Inhibitors; D010960:Plasminogen Activators / Q000032:analysis* / Q000037:antagonists & inhibitors*; D019714:Tissue Inhibitor of Metalloproteinases / Q000032:analysis*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D014945:Wound Healing / Q000502:physiology*; D014947:Wounds and Injuries / Q000201:enzymology* / Q000276:immunology*
D016207:Cytokines; D006133:Growth Substances; D007375:Interleukin-1; D015850:Interleukin-6; D061965:Matrix Metalloproteinase Inhibitors; D019714:Tissue Inhibitor of Metalloproteinases; D014409:Tumor Necrosis Factor-alpha; D010960:Plasminogen Activators; D019278:Matrix Metalloproteinase 3; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1